Heparin is not required for detection of antibodies associated with heparin-induced thrombocytopenia/thrombosis

被引:103
作者
Visentin, GP
Moghaddam, M
Beery, SE
McFarland, JG
Aster, RH
机构
[1] Blood Ctr SE Wisconsin Inc, Blood Res Inst, Milwaukee, WI 53201 USA
[2] Med Coll Wisconsin, Dept Med, Milwaukee, WI 53226 USA
[3] Med Coll Wisconsin, Dept Pathol, Milwaukee, WI 53226 USA
[4] Genet Testing Inst Inc, Milwaukee, WI USA
来源
JOURNAL OF LABORATORY AND CLINICAL MEDICINE | 2001年 / 138卷 / 01期
关键词
D O I
10.1067/mlc.2001.115525
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Heparin-induced thrombocytopenia (HIT), with or without thrombosis, is a common and often serious complication of heparin therapy. Platelet-activating, heparin-induced antibodies characteristic of HIT are thought to be specific for complexes formed between platelet factor 4 (PF4) and heparin, and such complexes are routinely used for antibody detection. We studied the binding of HIT antibodies to PF4 complexed with heparin fractions of uniform molecular size or linear polyanions other than heparin and found that many compounds other than heparin form complexes with PF4 that are suitable for antibody detection, provided they carry strong negative charges spaced about 0.5 nm apart along the molecular backbone and are of sufficient length to span about 40% of the circumference of the PF4 tetramer, Polyvinyl phosphonate was among the compounds that were equivalent to heparin. Thus neither a polysaccharide chain nor sulfate side groups-the hallmarks of heparin structure-are required for HIT antibody detection. The findings support the view that antibodies associated with HIT are specific for conformational changes that take place in the positively charged PF4 molecule when it reacts with a suitable, linear polyanion.
引用
收藏
页码:22 / 31
页数:10
相关论文
共 39 条
[31]  
Visentin GP, 1999, THROMB HAEMOSTASIS, V82, P448
[32]   ANTIBODIES FROM PATIENTS WITH HEPARIN-INDUCED THROMBOCYTOPENIA/THROMBOSIS ARE SPECIFIC FOR PLATELET FACTOR-4 COMPLEXED WITH HEPARIN OR BOUND TO ENDOTHELIAL-CELLS [J].
VISENTIN, GP ;
FORD, SE ;
SCOTT, JP ;
ASTER, RH .
JOURNAL OF CLINICAL INVESTIGATION, 1994, 93 (01) :81-88
[33]  
Warkentin T E, 1991, Prog Hemost Thromb, V10, P1
[34]   Heparin-induced thrombocytopenia - Pathogenesis, frequency, avoidance and management [J].
Warkentin, TE .
DRUG SAFETY, 1997, 17 (05) :325-341
[35]  
Warkentin TE, 1998, THROMB HAEMOSTASIS, V79, P1
[36]  
WARKENTIN TE, 1994, LOW MOL WEIGHT HEPAR, P75
[37]   Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor [J].
Xiao, ZH ;
Theroux, P .
CIRCULATION, 1998, 97 (03) :251-256
[38]   CRYSTAL-STRUCTURE OF RECOMBINANT HUMAN PLATELET FACTOR-4 [J].
ZHANG, XH ;
CHEN, LQ ;
BANCROFT, DP ;
LAI, CK ;
MAIONE, TE .
BIOCHEMISTRY, 1994, 33 (27) :8361-8366
[39]   Defining an antigenic epitope on platelet factor 4 associated with heparin-induced thrombocytopenia [J].
Ziporen, L ;
Li, ZQ ;
Park, KS ;
Sabnekar, P ;
Liu, WY ;
Arepally, G ;
Shoenfeld, Y ;
Kieber-Emmons, T ;
Cines, DB ;
Poncz, M .
BLOOD, 1998, 92 (09) :3250-3259